Summer Sale
50% off Premium Yearly
Opinions Jon Vialoux
Gilead Sciences Inc.GILDTOP PICKJun 11, 2015
Stock price when the opinion was issued
As of Jun 17, 2026. Market Open.
You might be interested:
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
Brian Belski
Jim Lebenthal;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Biotechs in general tend to do well from June 22 all the way to September 12. The industry on average gains about 12% and has been positive 85% of the time. There was a bit of resistance broken in April, and is now at new highs. These new highs would just entice investors back into it. This is the largest in the biotech industry. Alternatively, you could look at Abbott Labs (ABT-N), more of a pharmaceutical company, which tends to do well from August into the end of the year.